Search Results

You are looking at 61 - 70 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Cancer Screening: When Is the Juice Worth the Squeeze?

Margaret Tempero

doctors thinking? I don’t know what we spend on cancer screening in the United States, but I bet it’s a lot. A prostate-specific antigen (PSA) screen doesn’t cost much in itself, but the downstream cascade of procedures (biopsies, surgeries, and other

Full access

A Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Death

Hyung L. Kim, Marvin R. Puymon, Maochun Qin, Khurshid Guru, and James L. Mohler

Assessment) score. 7 Population-based cohort studies have defined the natural history of prostate cancer diagnosed in the pre–prostate-specific antigen (PSA) era and managed without curative treatment. Albertsen et al. 8 defined the risk for prostate cancer

Full access

Oncology Research Program

very high-risk prostate cancer or pelvic node–positive disease receiving radiotherapy. Very high-risk prostate cancer is defined as 2 or more of the following characteristics: (1) cT3a/b, (2) prostate-specific antigen (PSA) level of 20 ng/mL or greater

Full access

Prostate Cancer Active Surveillance: Quality Matters

Peter J. Van Veldhuizen

In 2012, the US Preventive Services Task Force made a Grade D recommendation against prostate-specific antigen (PSA) screening for all men based on the concern that PSA screening was leading to overtreatment with subsequent morbidity, and that

Full access

Reimagining Cancer Staging in the Era of Evolutionary Oncology

Kedar S. Kirtane, Mohammad U. Zahid, Heiko Enderling, and Louis B. Harrison

correlate with relevant genetic drivers, 6 to using prostate-specific antigen dynamics to predict response to androgen deprivation therapy. 5 There have been a number of studies using serial MRI data to make predictions about how a particular tumor will

Full access

Oncology Research Program

Estimate overall survival and time to prostate-specific antigen (PSA) progression Evaluate PSA and objective response Explore an angiogenesis signature that may predict benefit from vascular endothelial growth factor receptor-targeted therapy in

Full access

Oncology Research Program

Objectives: Demonstrate an acceptable tolerability profile of tivozanib and enzalutamide Estimate overall survival and time to prostate-specific antigen (PSA) progression Evaluate PSA and objective response Explore an angiogenesis signature that may

Full access

Highlights of the NCCN Oncology Research Program

progression by prostate-specific antigen (PSA) or bony metastasis and who are currently receiving combined androgen blockade with bicalutamide will receive temsirolimus weekly for 13 weeks. Because evaluating new therapies in prostate cancer is uniquely

Full access

Prostate Cancer, Version 2.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Maria Ho

Prostate cancer has surpassed lung cancer as the most common cancer in men. Experts generally accept that these changes resulted from prostate-specific antigen (PSA) screening that detected many early-stage prostate cancers. An estimated 233,000 new cases

Full access

Adapting Preclinical Concepts for Use in Clinical Trials of Serosal and Interstitial Photodynamic Therapy

Keith Cengel

can lead to severe toxicity, including fistulae. At higher light doses, where prostate necrosis occurs, significant prostate-specific antigen (PSA) responses can be seen. Finally, complete pathologic response is possible with low toxicity, but only